Safety and efficacy of dacomitinib in Korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: A phase I/II trial

Journal of Thoracic Oncology

Volumn 9, Issue 10, 2014, Pages 1523-1531

  Park, Keunchil ^a   Cho, Byoung C ^b   Kim, Dong Wan ^c   Ahn, Myung Ju ^a   Lee, Sang Yoon ^d   Gernhardt, Diana ^e   Taylor, Ian ^e   Campbell, Alicyn K ^e   Zhang, Hui ^e   Giri, Nagdeep ^e   Letrent, Stephen P ^e   O'Connell, Joseph ^f   Heo, Dae S ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Pfizer Korea   (South Korea)

^e PFIZER INC   (United States)

^f Pfizer Ltd   (United States)

Author keywords

Dacomitinib; Erlotinib; Gefitinib; Non small cell lung cancer; Refractory

Indexed keywords

DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHARMACOLOGICAL BIOMARKER; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; RAS PROTEIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DERMATITIS; DERMATOLOGY LIFE QUALITY INDEX; DIARRHEA; DISEASE COURSE; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; KOREAN (PEOPLE); LOSS OF APPETITE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSAL DISEASE; NAUSEA; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE; ADENOCARCINOMA; CLINICAL TRIAL; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; MULTICENTER STUDY; ONCOGENE RAS; PATHOLOGY; SOUTH KOREA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; QUINAZOLINONES; RAS PROTEINS; REPUBLIC OF KOREA; TREATMENT OUTCOME;

EID: 84925711517     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000275     Document Type: Article

References (37)

1. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-11932.
2. Shigematsu H, Takahashi T, Nomura M, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
3. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792.
4. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
5. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-6501.
6. Jänne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011;17:1131-1139.
7. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
8. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
9. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010;28:4769-4777.
10. Kris MG, Johnson BE, Kwiatkowski DJ. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29(Suppl.):Abstr. CRA7506.
11. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014;9:154-162.
12. Sun JM, Hwang DW, Ahn JS, Ahn MJ, Park K. Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. PLoS One 2013;8:e64816.
13. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
17. Aaronson NK, Cull A, Kaasa S, et al. The European Organization for Research and Treatment of Cancer (EORTC) Modular Approach to Quality of Life Assessment in Oncology: An Update, 2nd Ed. Philadelphia, Lippincott, 1996. pp. 179-189.
18. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30A:635-642.
19. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
20. Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 Reference Values. Available at: http://groups.eortc.be/qol/sites/default/files/img/newsletter/reference-values-manual2008.pdf. Accessed July 17, 2014.
21. Takahashi T, Boku N, Murakami H, et al. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 2012;30:2352-2363.
22. Janne P, Reckamp K, Koczywas M, et al. Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): a two-arm, phase II trial. J Clin Oncol 2009;27(15s Suppl.):Abstr. 8063.
23. Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3337-3344.
24. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470-481.
25. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107-119.
26. Ouwerkerk J, Boers-Doets C. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs 2010;14:337-349.
27. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-538.
28. th Congress of the European Society for Medical Oncology (ESMO), Milan, Italy, October 8-12, 2010.
29. Reckamp KL, Giaccone G, Camidge DR, et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 2014;120:1145-1154.
30. Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013;31:3335-3341.
31. Peppercorn JM, Smith TJ, Helft PR, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011;29:755-760.
32. Gregorc V, Ceresoli GL, Floriani I, et al. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10(18, Part 1):6006-6012.
33. Kappers I, Vollebergh MA, van Tinteren H, et al. Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. Ecancermedicalscience 2010;4:178.
34. Ardizzoni A, Cafferata MA, Paganuzzi M, et al. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma. Cancer 2001;92:1896-1904.
35. Maramotti S, Paci M, Miccichè F, et al. Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood. Lung Cancer 2012;76:332-338.
36. Kelly RJ, Carter C, Giaccone G. Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. J Clin Oncol 2010;28:e507-e510.
37. Press release: Pfizer's lung cancer drug dacomitinib fails in two phase 3 trials. Available at: http://www.drugdevelopment-technology.com/news/newspfizers-lung-cancer-drug-dacomitinib-fails-in-two-phase-iiitrials-4166620. Accessed January 28, 2014.